Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit – if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. The pace and demand are picking up in the United States. In other countries, including some where the research took place, there is limited or no access. For maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research, and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills, or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

Key Update

A range of antiretroviral based prevention trials released data providing strong new evidence for how well daily oral pre-exposure prophylaxis (PrEP) work to prevent new HIV infections. The studies were presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).

February 26, 2015
Voice of America
What We're Reading

Dawn Smith and colleagues at the CDC published estimates of the combination effectiveness of PrEP and condoms among African-American men who have sex with men, strengthening arguments about high-impact combination prevention programs.

January 14, 2015
Journal of the American Sexually Transmitted Diseases Association

In late December 2014, data on knowledge, attitudes and likelihood of PrEP use in US women was published in the journal AIDS Patient Care and STDs. The study was conducted by AIDS United and included focus group discussions with 150+ women from across the United States. Key findings include women’s interest in PrEP as an additional prevention tool and identification of potential barriers that to be addressed to provide access for women in the US.

December 16, 2014
AIDS Patient Care and STDs

Given the recent positive news from the PROUD and IPERGAY PrEP trials, gay men’s health and LGBT groups joined several AIDS service organizations in the UK to call for the NHS, the UK’s publicly funded healthcare system, to speed up its evaluation process and make PrEP available as soon as possible. Read the full statement here.

November 25, 2014
Subscribe to RSS - PrEP